Zydus Cadila Gets USFDA Nod For Generic Antiviral Drug, Atazanavir Capsules
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Atazanavir capsules, an antiviral drug, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Atazanavir capsules in strengths of 150 mg, 200 mg and 300 mg, Zydus Cadila said in a statement.
Atazanavir, an antiretroviral drug, is used to treat Human Immunodeficiency Virus (HIV-1) infection incombination with other antiretroviral drugs.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The Zydus Group now has 291 approvals and has so far filed over 390 abbreviated new drug application (ANDAs) since the commencement of the filing process in 2003-04, the company said.
HSBC Swings The Axe At UK Wealth In An AI Push
HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more
Kraken's Owner Buys A Bank: The Lines Are Blurring
Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
Bank Of London Continues To Rebuild
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more